Angiology;Angiologie

Medizinische Klinik

Volumn 103, Issue 4, 2008, Pages 198-209

  Lawall, Holger ^a   Diehm, Curt ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Aortic aneurysm; Carotid stenoses; Peripheral arterial disease; Renal artery stenoses; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRIC ACID DERIVATIVE; FONDAPARINUX; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THROMBIN INHIBITOR;

ABDOMINAL AORTA ANEURYSM; ANGIOLOGY; ARTERY DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CLINICAL FEATURE; CLINICAL STUDY; CORONARY STENT; HEART HEMODYNAMICS; HUMAN; INTERVENTION STUDY; KIDNEY ARTERY STENOSIS; MEDICAL INSTRUMENTATION; PROPHYLAXIS; REVIEW; SURGICAL TECHNIQUE; TREATMENT INDICATION; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM;

ANGIOPLASTY, BALLOON; AORTIC ANEURYSM, ABDOMINAL; CAROTID STENOSIS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; META-ANALYSIS AS TOPIC; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL ARTERY OBSTRUCTION; STENTS; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 43949096571     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-008-1029-8     Document Type: Review

References (112)

1. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
2. Futterman LG, Lemberg L. Peripheral arterial disease is only the tip of the atherosclerotic iceberg. Am J Crit Care 2002;11:390-4.
3. Oelert H, Meyer J. Diagnose und Therapie von Gefäßkrankheiten. Med Klin 2002;97:191-2.
4. Heller G, Günster C, Schellschmidt H. Wie häufig sind Diabetes-bedingte Amputationen unterer Extremitäten in Deutschland? Dtsch Med Wochenschr 2004;129:429-33.
5. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness and treatment in primary care. JAMA 2001;286;1317-24.
6. Hirsch AT, Halverson SL, Treat-Jacobson D, et al. The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care. Vasc Med 2001;6:87-96.
7. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004;172:95-105.
8. Fowkes FG. Epidemiological research on peripheral arterial disease. J Clin Epidemiol 2001;54:863-8.
9. Criqui MH. Peripheral arterial disease - epidemiological aspects. Vasc Med 2001;6:3-7.
10. Diehm C, Lange S, Darius H, et al., for the getABI Study Group. Association of low ankle brachial index with high mortality in primary care. Eur Heart J 2006;27:1743-9.
11. Ouriel K. Peripheral arterial disease. Lancet 20 01;358:1257-64.
12. Hirsch AT, Treat-Jacobson D, Lando HA, et al. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med 1997;2:243-51.
13. Willigendael EM, Teijink JA, Bartelink ML, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004;40:1158-65.
14. Bendermacher BLW, Willigendael EM, Teijink JA, et al. Medical management of peripheral arterial disease. J Thromb Haemost 2005;3:1628-37.
15. Egan DA, Garg R, Wilt TJ, et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. Am J Cardiol 1999;83:569-75.
16. Pederson TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998;81:333-5.
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
18. Aronow WS, Nayak D, Woodworth S, et al. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003;92:711-2.
19. McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003;107:757-61.
20. Mohler ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with arterial disease. Circulation 2003;108:1481-6.
21. Adler AI, Stevens RJ, Neil A, et al. UKPDS 59: hyperglycemia and other potential risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002;25:894-9.
22. Dolan NC, Liu K, Criqui MH, et al. Peripheral artery disease, diabetes and reduced lower extremity functioning. Diabetes Care 2002;25:113-20.
23. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003;26:3333-41.
24. Gaede P, Vedel P, Larsen N et al. Steno type 2 randomised study. N Engl J Med 2003;348:383-93
25. Mehler PS, Coll JR, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107:753-80.
26. Rauch U, Osende JI, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001;134:224-38.
27. Hiatt WR. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy. J Intern Med 2002;251:193-206.
28. Antithrombotic Trialists' Collaboration. Impact of antiplatelet therapy on peripheral arterial disease. BMJ 2002;324:71-86.
29. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1-12.
30. De Schryver ELM, Algra A, van Gijn J. Cochrane Review: Dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 2003;34:2072-7.
31. Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;124:609-26.
32. Dutch Bypass Oral anticoagulants or Asprin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery: a randomised trial. Lancet 2000;355:346-51.
33. Johnson WC, Williford WO Point P. Benefits, morbidity and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomised study. J Vasc Surg 2002;35:413-21.
34. Shlansky-Goldberg R. Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries? J Vasc Interv Radiol 2002;13:229-46.
35. Hoeks SE, Scholte op Reimer WJM, van Urk H, et al. Increase of 1-year mortality after perioperative beta-blockers withdrawal in endovascular and vascular surgery patients. Eur J Vasc Endovasc Surg 2007;33:13-9.
36. Fernando SK, Atlas SA. Increasing perioperative beta-blocker utilization: a successful quality improvement project. Am J Med 2005;118:802-3.
37. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004;351;2795-804.
38. Rath K, Schäfer HG, Mörl H. Prävention und Rehabilitation von arteriellen peripheren Durchblutungsstörungen im Alter. Internist (Berl) 2002;43:949-58.
39. Schulte KL. Interventionelle endovaskuläre Therapie bei Patienten mit peripherer arterieller Verschlusskrankheit - Ballonangioplastie. Vasa 2004;33:Suppl 64:5-7.
40. Amendt K. Ist der allgemein akzeptierte therapeutische Nutzen des Gehtrainings bei Patienten mit arterieller Verschlusskrankheit evidenzbasiert? Analyse des Cochrane-Reviews. Hämostaseologie 2006;26:224-8.
41. Steinacker JM, Liu Y, Hanke H. Körperliche Bewegung bei peripherer arterieller Verschlusskrankheit. Dtsch Ärztebl 2002;45:2550-4.
42. Gardner AW, Katzel LI, Sorkin JD, et al. Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial. J Am Geriatr Soc 2001;49:755-62.
43. Katzel LI, Sorkin JD, Powell C, et al. Comorbidities and exercise capacity in older patients with intermittent claudication. Vasc Med 2001;6:157-62.
44. Stewart KJ, Hiatt WR, Regensteiner JG, et al. Exercise training for claudication. N Engl J Med 2002;347:1941-51.
45. Dean SM. Pharmacologic treatment for intermittent claudication. Vasc Med 2002;7:301-9.
46. Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on walking distance in patients with claudication. Ann Cardiol Angeiol (Paris) 2001;50:175-82.
47. Leitlinien zur Diagnostik und Therapie der arteriellen Verschlusskrankheit der Becken-Beinarterien. Vasa 2001;30:Suppl 57:1-19.
48. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608-21.
49. Hiatt WR. The US experience with cilostazol in treating intermittent claudication. Atheroscler Suppl 2006;6:21-31.
50. Regensteiner JG, Ware JE, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health related QOL in patients with intermittent claudication due to peripheral disease: metaanalysis of six randomised controlled trials. J Am Geriatr Soc 2002;50:1939-46.
51. Bradbury AW. The role of cilostazol in the management of intermittent claudication. Int J Clin Pract 2003;57:405-9.
52. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. J Vasc Surg 2000;31:1-296.
53. The ICAI Study Group. Prostanoids for chronical critical leg ischemia. Ann Intern Med 1999;130:412-21.
54. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC study): a randomised trial. Lancet 2002;359:2053-8.
55. Lawall H. Gen- und autologe Stammzelltherapie bei pAVK mit chronischer Extremitätenischämie. Hämostaseologie 2006;26:247-54.
56. Wagner HJ. Zum aktuellen Stellenwert der endovaskulären Therapie im femoropoplitealen Abschnitt bei chronischer Extremitätenischämie. Vasa 2002;31:153-61.
57. Garasic JM, Creager MA. Percutaneous interventions for lower-extremity peripheral atherosclerotic disease. Rev Cardiovasc Med 2001;2:120-5.
58. Faries P, Morrissey NJ, Teodorescu V, et al. Recent advances in peripheral angioplasty and stenting. Angiology 2002;53:617-26.
59. Lugmayr HF, Holzer H, Kastner M, et al. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a mid-term follow-up. Radiology 2002;222:37-43.
60. Duda S, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease. Circulation 2002;106:1505-11.
61. Duda S, Heller S, Wiesinger B, et al. Modifizierte Stents für die interventionelle Therapie der pAVK. Vasa 2004;33:Suppl 64:55-9.
62. Jahnke T, Voshage G, Muller-Hulsbeck S, et al. Endovascular placement of self-expanding nitinol coil stents in the treatment of femoropopliteal obstructive disease. J Vasc Interv Radiol 2002;13:257-66.
63. Jamsen TS, Manninen HI, Tulla HE, et al. Infrainguinal revascularisation because of claudication: total long-term outcome of endovascular and surgical treatment. J Vasc Surg 2003;37:808-15.
64. Jahnke T, Andresen R, Muller-Hulsbeck S, et al. Hemobahn stent-grafts for the treatment of femoropopliteal artery obstructions: mid-term results of a prospective trial. J Vasc Interv Radiol 2003;14:41-51.
65. Tefera G, Turnipseed W, Tanke T. Limb salvage angioplasty in poor surgical candidates. Vasc Endovasc Surg 2003;37:99-104.
66. Lofberg AM, Karacagil S, Ljungman C, et al. Percutaneous angioplasty of the femoropopliteal arteries in limbs with chronic critical lower limb ischemia. J Vasc Surg 2001;34:114-21.
67. Jamsen TS, Manninen HI, Jaakkola PA, et al. Long-term outcome of patients with claudication after balloon angioplasty of the femoropopliteal arteries. Radiology 2002;225:345-52.
68. Brillu C, Picquet J, Villapardierna F, et al. Percutaneous angioplasty for management of critical ischemia in arteries below the knee. Ann Vasc Surg 2001; 15:175-81.
69. Uher P, Nyman U, Lindh M, et al. Long-term results of stenting for chronic iliac artery occlusion. J Endovasc Ther 2002;9:67-75.
70. Pozzi MF, Fisicaro M, Calderan L, et al. Percutaneous revascularisation of femoropopliteal artery disease: PTA and PTA plus stent. Results after six years follow-up. Radiol Med 2003;105:339-49.
71. Soder HK, Manninen HI, Jaakkola P, et al. Prospective trial of infrapopliteal artery balloon angioplasty critical limb ischemia: angiographic and clinical results. J Vasc Interv Radiol 2000;11:1021-31.
72. Comerota AJ. Endovascular and surgical revascularisation for patients with intermittent claudication. Am J Cardiol 2001;87:34-43.
73. Norgren L, Hiatt W, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33:1-75.
74. Sigala F, Georgopoulos S, Langer S, et al. Outcome of infrainguinal revascularization for critical limb ischemia in diabetics with end stage renal disease. Vasa 2006;35:15-20.
75. Faglia E, Mantero M, Caminiti M, et al. Extensive use of peripheral angioplasty in the treatment of ischemic diabetic foot ulcers: clinical results of a multicentric study of consecutive diabetic subjects. J Intern Med 2002;252:225-32.
76. BASIL Trial Investigators. Bypass versus angioplasty in severe ischemia of the leg (BASIL): multicentre, randomized controlled trial. Lancet 2005;366:1925-34.
77. Lederle FA. Ultrasonographic screening for abdominal aortic aneurysms. Ann Intern Med 2003;139:516-22.
78. Miraude E, Adriaensen PM, Bosch JL, et al. Elective endovascular versus open surgical repair of abdominal aortic aneurysms: systematic review of short-term results. Radiology 2002;224:739-47.
79. Greenhalgh RM, Brown LC, Kwong GP, et al. Comparison of endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet 2004;364:843-8.
80. Blankensteijn JD, de Jong SEC, Prinssen M, et al., for the DREAM Trial Group. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med 2005;352:2398-405.
81. Greenhalgh RM, Brown LC, Powell JT, et al. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. Lancet 2005;365:2187-92.
82. Rundback JH, Sacks D, Kent C, et al. Guidelines for the reporting of renal artery revascularisation in clinical trials. Circulation 2002;106:1572-85.
83. Harden PN, MacLeod MJ, Rodger RSC, et al. Effect of renal artery stenting on progression of renovascular renal failure. Lancet 1997;349:1133-6.
84. Van de Ven PJG, Kaatee R, Beutler JJ, et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial. Lancet 1999;353:282-6.
85. Van Jaarsfeld BC, Krijnen P, Pieterman H, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 2000;342:1007-14.
86. Zeller T, Frank U, Müller C. Stent-supported angioplasty of severe atherosclerotic renal artery stenosis preserves renal function and improves blood pressure control: long-term results of a prospective registry with 456 lesions. J Endovasc Ther 2004;11:95-106.
87. Sapoval M, Zähringer M, Pattynamma P, et al. Low-profile stent system for treatment of atherosclerotic renal artery stenosis: The GREAT Trial. J Vasc Interv Radiol 2005;16:1195-202.
88. Nordmann AJ, Logan AG. Ballon angioplasty versus medical therapy for hypertensive patients with renal artery obstruction. Cochrane Database Syst Rev 2003;3:CD002944.
89. Zeller T. Diagnosis and endovascular treatment of renal artery stenosis. Vasa 2006;35:147-55.
90. Radermacher J, Chavan A, Bleck J, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001;344:410-7.
91. Zeller TH, Müller C, Frank U, et al. Stent angio plasty of severe atherosclerotic ostial renal artery stenosis in patients with diabetes mellitus and nephrosclerosis. Cathet Cardiovasc Interv 2003;58:510-5.
92. Watson PS, Hadjipetrou P, Cox SV, et al. Effect of renal artery stenting on renal function and size in patients with atherosclerotic renovascular disease. Circulation 2000;102:1671-7.
93. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998;339:1415-25.
94. European Carotid Surgery Trialists' Collaborative Group. Randomized trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1999;351:1379-87.
95. Rothwell P, Eliasziw M, Gutnikow S, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004;363:915-24.
96. Mas JL, Chatellier G, Beyssen B et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006;355:1660-71.
97. CAVATAS Investigators. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomized trial. Lancet 2001;357:1729-37.
98. Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004;351:1493-501.
99. Theiss W, Hermanek P, Mathias K, et al. Pro-CAS. A prospective registry of carotid angioplasty and stenting. Stroke 2004;35:2134-9.
100. Hobson RW, Howard VJ, Roubin GS, et al. Carotid artery stenting is associated with increased complications in octogenarians. 30-day stroke and death rate in the CREST lead-in phase. J Vasc Surg 2004;40:1106-11.
101. Mudra H, Büchele W, Mathias K, et al. Positionspapier zur Indikation und Durchführung der interventionellen Behandlung extrakranieller Karotisstenosen. Vasa 2006;35:125-31.
102. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338-400.
103. Haas S, Bauersachs R, Hach-Wunderle V, et al. Abschätzung des Thromboserisikos bei internistischen Patienten. Phlebologie 2005;34:87-93.
104. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005;3:1611-7.
105. Bauersachs R. Therapie der Beinvenenthrombose. Internist (Berl) 2004;45:1345-55.
106. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401-28.
107. Buller HR, Davidson BL, Decous H et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867-73.
108. The MATISSE Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702.
109. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-9.
110. Vink R, Kraaijenhagen RA, Levi M, et al. Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model. J Thromb Haemost 2003;1:2523-30.
111. Schmidt B, Schellong S. Thrombophile Störungen bei venöser Thrombophilie. Med Klin 2003;98:133-9.
112. Ho WK, Hankey GJ, Quinlan DJ, et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia. Arch Intern Med 2006;166:729-36.